Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study from the EUSTAR Cohort.

Arthritis care & research·2026
Same author

Influence of comorbidities and patient demographics on Raynaud's symptom characteristics: implications for diagnosis and management.

Journal of scleroderma and related disorders·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Pulmonary arterial hypertension susceptibility and mortality among patients with systemic sclerosis with the DNASE1L3 rs35677470 (Arg206Cys) variant.

Annals of the rheumatic diseases·2026
Same journal

Time to rethink the treatment of palindromic rheumatism.

Nature reviews. Rheumatology·2026
Same journal

Sensory nerves protect against tendon degeneration.

Nature reviews. Rheumatology·2026
Same journal

Publisher Correction: TLR7 in systemic lupus erythematosus: genetics and emerging therapies.

Nature reviews. Rheumatology·2026
Same journal

TLR7 in systemic lupus erythematosus: genetics and emerging therapies.

Nature reviews. Rheumatology·2026
Same journal

Lung disease in rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same journal

Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis.

Nature reviews. Rheumatology·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Targeted therapies for systemic sclerosis.

Christopher P Denton1, Voon H Ong

  • 1Centre for Rheumatology and Connective Tissue Disease, UCL Medical School, Royal Free Hospital, London NW3 2QG, UK. c.denton@ucl.ac.uk

Nature Reviews. Rheumatology
|April 10, 2013
PubMed
Summary
This summary is machine-generated.

Targeted therapies are emerging for systemic sclerosis (SSc), focusing on immune and vascular pathways. Research aims to modify SSc progression and improve tissue function, offering hope for antifibrotic treatments.

Related Experiment Videos

Last Updated: May 12, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Immunology
  • Vascular Biology
  • Rheumatology

Background:

  • Systemic sclerosis (SSc) pathogenesis involves complex interactions between vasculature, connective tissue, and immune systems.
  • Abnormalities in both innate and adaptive immunity are identified in SSc development and progression.
  • Preclinical and clinical studies are defining key mediators and pathways in SSc.

Purpose of the Study:

  • To review the concept of targeted therapies for systemic sclerosis (SSc).
  • To identify potential therapeutic targets and pathways for disease modification in SSc.
  • To discuss the potential for antifibrotic treatments and their implications beyond SSc.

Main Methods:

  • Review of preclinical and clinical studies on SSc pathogenesis.
  • Analysis of genetic studies to identify disease-related pathways.
  • Examination of ongoing and planned clinical trials for SSc therapies.

Main Results:

  • Evidence suggests interplay between vasculature, connective tissue, and epithelial structures in SSc.
  • Immune system abnormalities are crucial in SSc pathogenesis.
  • Clinical studies indicate potential for improving tissue structure and function in SSc.

Conclusions:

  • Targeted therapies offer potential for true disease modification in SSc.
  • Antifibrotic treatments are a key goal, with clinical trials underway.
  • Advances in SSc therapy have broader implications for autoimmune rheumatic diseases.